MediGene, Johns Hopkins join on HPV vax research

MediGene, a Martinsried/Munich-based biotech, and The Johns Hopkins University will work together to create HPV vaccine candidates using the German firm's AAVLP platform. The preclinical program uses adeno-associated viruses as the basis for the vaccine and antigenic peptides to induce specific antibody reactions. MediGene hopes the platform can be used for viral infection and cancer vaccines as well. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.